2025年10月20日,默沙东在2025欧洲肿瘤内科学会(ESMO)年会发布部分早期及晚期非小细胞肺癌(NSCLC)患者长期生存数据进展。此次数据源于多项研究长期分析,包括KEYNOTE-671研究五年探索性随访分析,评估帕博利珠单抗作为可切除NSCLC患者围术期治疗方案的应用;以及KEYNOTE-024和KEYNOTE-042的八年分析、KEYNOTE-001和KEYNOTE-010的十年分析,...
Source Link2025年10月20日,默沙东在2025欧洲肿瘤内科学会(ESMO)年会发布部分早期及晚期非小细胞肺癌(NSCLC)患者长期生存数据进展。此次数据源于多项研究长期分析,包括KEYNOTE-671研究五年探索性随访分析,评估帕博利珠单抗作为可切除NSCLC患者围术期治疗方案的应用;以及KEYNOTE-024和KEYNOTE-042的八年分析、KEYNOTE-001和KEYNOTE-010的十年分析,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.